
Opinion|Videos|September 16, 2024
Challenges in Managing Co-Morbid CRM Conditions
Key Takeaways
- Polypharmacy and drug-drug interactions complicate the management of co-morbid CRM conditions, necessitating careful medication review and adjustment.
- Overlapping symptoms of CRM conditions require a multidisciplinary approach for accurate diagnosis and effective management.
A panel of medical experts examines the challenges in managing co-morbid cardiometabolic conditions, emphasizing the most prevalent complications associated with this disease state.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What are the major clinical challenges in managing patients with co-morbid CRM conditions?
This activity is supported by Boehringer Ingelheim Pharmaceuticals Inc. and Eli Lilly and Company who provided financial support for this program.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Nerandomilast for Idiopathic Pulmonary Fibrosis
2
Pulling Back Funding for Research Could Leave HIV Treatment in Worse State: Patrick Sullivan, DVM, PhD
3
FDA Approves Cemiplimab as First, Only Adjuvant Immunotherapy for High-Risk CSCC
4
Value-Based Care Interventions and Management of CKD Progression
5